Developments in High-Yield System Expressed Vaccines and Immunotherapy

Marissa      Geels; Kaiming      Ye

Abstract

Conventional vaccine production techniques are outdated, leaving the world defenseless to viruses and pathogens. Successful protection necessitates the innovation of strategies that can generate an induced defensive humoral and cellular response with: ease of mass production, nominal side-effects, and controlled design specificity, all while being cost effective. Fortunately, technology exists to facilitate such advances in this billion dollar industry and this review is focused on recent publications and patents which hold promise to revolutionize the fight against pathogenic illnesses.

Keywords: Cell surface protein display, viral vectors, antigen delivery systems, influenza vaccine, immunotherapy, vaccine production, patho-genic organism, pandemic, shelf-life, mutations, zoonotic infections, virus, swine, cell-mediated, humoral immunity, polypeptides, polynucleotide, polyethylene glycol precipitation, ultra-filtration, non-structural proteins, allergic reactions, antigens, bioreactor, immunization, prophylactic, memory T cells, nontypable, Haemophilus Influenza (NTHi), adhesion pro-teins, toxin, blood coagulation factors, polio, yellow fever, RNA, Orthomyxoviridae, formaldehyde treatment, High-growth, heterologous flaviviruses, polymerase, salmonella, B-cell, antitoxin, epitopes, Pfeiffer's bacillus, noncytopathic virus, anti-hpv, rotavirus, poxviruses, herpesvi-rus, adenovirus, baculovirus, rhabdovirus, lymphocyte, Microbial systems, carrier protein, enzymes, hepatitis B virus (HBV), patent, Beta-amyloid peptide, Alzheimer's disease, emulsifying agents, wetting agents, phagocytic cells, intramuscular, verses intranasal, IgG, tissue trauma, antiviral barrier, mucosa, dosage requirements, stimulators, immune system